

**AWMSG ADVICE SUPERSEDED BY
NICE GUIDANCE (TA455)
NICE GUIDANCE ISSUED JULY 2017**

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Final Appraisal Recommendation

Advice No: 0416 – February 2016

Ustekinumab (Stelara[®]) 45 mg solution for injection, 45 mg and 90 mg solution for injection in pre-filled syringe

Limited submission by Janssen-Cilag Ltd

Recommendation of AWMSG

Ustekinumab (Stelara[®]) is recommended as an option for use within NHS Wales for the treatment of chronic moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.

Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2068), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review every three years.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 0416:
ustekinumab (Stelara[®]) 45 mg solution for injection, 45 mg and 90 mg solution for injection in
pre-filled syringe. February 2016.

